metformin has been researched along with Liver Cirrhosis in 77 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 9.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
| "A PubMed (1946-August 2013) search using the keywords type 2 diabetes mellitus, metformin, hepatitis C virus, cirrhosis, and hepatocellular carcinoma was conducted." | 8.89 | Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. ( Harris, K; Smith, L, 2013) |
| "The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study." | 8.31 | Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023) |
| " The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before." | 8.31 | Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023) |
| "Metformin use was associated with higher risks of mortality and cirrhotic decompensation in patients with compensated liver cirrhosis." | 8.12 | Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. ( Hou, MC; Hsu, CC; Huang, YH; Hwu, CM; Lo, YR; Shin, SJ; Yen, FS, 2022) |
| "To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients." | 7.78 | Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. ( Ampuero, J; Bautista, JD; Camacho, I; del Campo, JA; Díaz-Herrero, Mdel M; Figueruela, B; Maraver, M; Nuñez, D; Ranchal, I; Rojas, Á; Romero-Gómez, M, 2012) |
| "Liver fibrosis is a disease with significant morbidity and mortality." | 7.01 | Research progress of metformin in the treatment of liver fibrosis. ( Hu, C; Huang, Y; Li, B; Li, Y; Qian, F; Sun, W; Yang, F; Zhang, A, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of liver disease worldwide." | 6.90 | Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. ( Duława, J; Handzlik, G; Holecki, M; Kędzierski, L; Kozaczka, J; Kukla, M; Pawlicki, K; Wyskida, K, 2019) |
| "Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters." | 6.82 | Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "Metformin is an attractive agent for chemoprevention because it is inexpensive, has a favorable safety profile, and is well tolerated over long time periods." | 5.43 | Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. ( Chung, RT; DePeralta, DK; Fuchs, BC; Ghoshal, S; Lanuti, M; Lauwers, GY; Schmidt, B; Tanabe, KK; Wei, L, 2016) |
| "Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes." | 5.38 | Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012) |
| "Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 5.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
| "A PubMed (1946-August 2013) search using the keywords type 2 diabetes mellitus, metformin, hepatitis C virus, cirrhosis, and hepatocellular carcinoma was conducted." | 4.89 | Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. ( Harris, K; Smith, L, 2013) |
| "The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study." | 4.31 | Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023) |
| " The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before." | 4.31 | Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023) |
| "Metformin use was associated with higher risks of mortality and cirrhotic decompensation in patients with compensated liver cirrhosis." | 4.12 | Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. ( Hou, MC; Hsu, CC; Huang, YH; Hwu, CM; Lo, YR; Shin, SJ; Yen, FS, 2022) |
| "Metformin use in patients with cirrhosis and diabetes appears safe and is associated independently with reduced overall, but not liver-related, mortality, hepatocellular carcinoma, or decompensation after adjusting for concomitant statin and angiotensinogen-converting enzyme inhibitor/angiotensin-2-receptor blocker exposure." | 4.02 | Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. ( Albrecht, J; Aytaman, A; Baytarian, M; Fox, R; Hunt, K; John, BV; Kaplan, DE; Lerer, R; Mehta, R; Serper, M; Taddei, TH; Tessiatore, KM, 2021) |
| "Our study demonstrated an association between long-term metformin use and reduced the risk of all-cause mortality/transplant and hepatocellular carcinoma in diabetics with non-alcoholic steatohepatitis and advanced fibrosis." | 3.91 | Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. ( Chalasani, N; Cummings, OW; Desai, AP; Gawrieh, S; Ghabril, M; Saxena, R; Vilar-Gomez, E; Vuppalanchi, R, 2019) |
| "To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients." | 3.78 | Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. ( Ampuero, J; Bautista, JD; Camacho, I; del Campo, JA; Díaz-Herrero, Mdel M; Figueruela, B; Maraver, M; Nuñez, D; Ranchal, I; Rojas, Á; Romero-Gómez, M, 2012) |
| "A total of 100 consecutive diabetic patients (53 men, age 61 ± 11 yr) with ongoing HCV cirrhosis and no contraindication for metformin were included in a screening program for hepatocellular carcinoma (HCC)." | 3.77 | Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. ( Aout, M; Beaugrand, M; Bourcier, V; Charif, I; Cosson, E; Ganne-Carrie, N; Grando-Lemaire, V; Mahmoudi, A; Nkontchou, G; Trinchet, JC; Vicaut, E, 2011) |
| "Liver fibrosis is a disease with significant morbidity and mortality." | 3.01 | Research progress of metformin in the treatment of liver fibrosis. ( Hu, C; Huang, Y; Li, B; Li, Y; Qian, F; Sun, W; Yang, F; Zhang, A, 2023) |
| "Portal hypertension is the main determinant of clinical decompensation in patients with liver cirrhosis." | 3.01 | Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. ( Aagaard, NK; George, J; Grønbaek, H; Jessen, N; Rittig, N; Sandahl, TD; Villadsen, GE, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of liver disease worldwide." | 2.90 | Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. ( Duława, J; Handzlik, G; Holecki, M; Kędzierski, L; Kozaczka, J; Kukla, M; Pawlicki, K; Wyskida, K, 2019) |
| "Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters." | 2.82 | Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "However, most patients with NAFLD/NASH will die from a vascular cause." | 2.72 | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. ( Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in both adults and children." | 2.66 | Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. ( Kohli, R; Lin, CH, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and comprises a liver disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) with risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC)." | 2.52 | Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. ( Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Munda, P; Rechling, C; Trauner, M; Traussnigg, S, 2015) |
| "Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk." | 2.47 | [Fatty liver and its clinical management in obese adolescents]. ( Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J, 2011) |
| "Insulin resistance is considering as having a central role in NAFLD pathogenesis." | 2.44 | [Non-alcoholic fatty liver disease--new view]. ( Lawniczak, M; Marlicz, W; Miezyńska-Kurtycz, J; Milkiewicz, P; Raszeja-Wyszomirska, J, 2008) |
| "Nonalcoholic steatohepatitis (NASH) is one of the most common liver disorders in North America." | 2.44 | Treatment of fibrosis in nonalcoholic fatty liver disease. ( Anania, FA; Hoteit, MA, 2007) |
| "The extent of liver fibrosis, ranging from fibrosis stage (FS) of none (F0) to cirrhosis (F4), is a strong predictor of health outcomes." | 1.91 | Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. ( Articolo, A; Charlton, M; Luthra, R; Shelley, K, 2023) |
| "Metformin can inhibit HSCs; however, no systematic studies demonstrating the effects of metformin on mitochondria in HSCs have been reported." | 1.91 | Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis. ( Hou, C; Liu, X; Ren, K; Su, Y; Wang, M; Zhao, S; Zhou, D, 2023) |
| "At EOS, subjects with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis versus conventional therapy; the severity of hepatic steatosis and fibrosis were both strongly and inversely correlated with insulin resistance; and changes in liver fibrosis scores (APRI, NFS, Fibrosis-4, and AST/ALT ratio) have limited value in predicting response to therapy." | 1.72 | Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). ( Abdelgani, S; Abdul-Ghani, M; Adams, J; Alatrach, M; Alkhouri, N; Cersosimo, E; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Lavynenko, O; Li, J; Puckett, C; Triplitt, C; Vasquez, JA, 2022) |
| "Central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are the major risk factors for NAFLD." | 1.72 | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. ( Cui, W; Kong, L; Yang, X; Zhou, ST, 2022) |
| "Incident ascites was associated with increased risk of death, HR 27." | 1.72 | Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. ( Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z, 2022) |
| "The changes that follow liver fibrosis were assessed by measurement of hepatic enzymes (ALT, AST and ALP), histopathological examination using hematoxylin and eosin stain, special stains, and α-smooth muscle actin (α-SMA) immunostaining, measuring oxidative stress markers (MDA, GSH, NOx and MnSOD) and transforming growth factor-beta 1 (TGF-β1) in liver." | 1.72 | Metformin versus silymarin as hepatoprotective agents in mice fibrotic model caused by carbon tetrachloride. ( Ahmed, AA; Ahmed, MA; El-Bakry, MH; Hasan, A; Omar, ZMM, 2022) |
| "The incidence of hepatocellular carcinoma (HCC) in the United Kingdom has increased 60% in the past 10 years." | 1.72 | The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival. ( Berhane, S; Cuthbertson, DJ; Dhanaraj, S; Graef, S; Hydes, TJ; Johnson, PJ; Singh, P; Skowronska, A; Tahrani, A; Teng, M, 2022) |
| "We investigated the evolution of liver fibrosis and steatosis during 2-year use of metformin in patients with T2DM." | 1.62 | Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. ( Ahn, SH; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Lee, JS; Park, JY, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading liver disease globally." | 1.62 | Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. ( Gawrieh, S; Khneizer, G; Rizvi, S, 2021) |
| "Metformin use over time was associated with a significant reduction in risk of death or liver transplantation (aHR, 0." | 1.62 | Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. ( Adams, LA; Aller-de la Fuente, R; Calzadilla-Bertot, L; Castellanos, M; Eslam, M; George, J; Romero-Gomez, M; Vilar-Gomez, E; Wong, GL; Wong, VW, 2021) |
| "In our cohort of T2D with biopsy proven NAFLD, the patients who were receiving metformin, liraglutide, lisinopril, hydrochlorothiazide, atorvastatin and simvastatin were less likely to have AF on biopsy, while patients who were receiving furosemide and spironolactone had a higher likelihood of having AF when they underwent liver biopsy." | 1.56 | Medications in type-2 diabetics and their association with liver fibrosis. ( Al-Yaman, W; Amin, H; Chadalavada, P; Garg, R; Lopez, R; Siddiqui, MT; Singh, A, 2020) |
| "Metformin ameliorated steatohepatitis, liver fibrosis, inflammatory cytokine production and decreased α -SMA and GPR91expression in the livers of the MCD diet-fed mice." | 1.48 | Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition. ( Cho, EH; Choi, DH; Le, CT; Nguyen, G; Park, SY; Park, WS, 2018) |
| "Metformin is an anti-diabetic agent which possesses anti-inflammation and anti-angiogenesis properties." | 1.46 | Metformin reduces intrahepatic fibrosis and intrapulmonary shunts in biliary cirrhotic rats. ( Chang, CC; Chuang, CL; Hsin, IF; Hsu, SJ; Huang, HC; Ko, MT; Lee, FY; Lee, SD; Lee, WS, 2017) |
| "Hepatocellular carcinoma is the most common primary liver malignancy, commonly a sequelae of hepatitis C infection, but can complicate cirrhosis of any cause." | 1.46 | Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. ( Kasmari, AJ; Leslie, D; Liu, G; McGarrity, T; Riley, T; Welch, A, 2017) |
| "A total of 109 patients who had chronic hepatitis B and were receiving NA therapy were analyzed." | 1.43 | Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. ( Arai, K; Honda, M; Kaneko, S; Kawaguchi, K; Mizukoshi, E; Nakamura, M; Oishi, N; Okada, H; Sakai, Y; Shimakami, T; Shirasaki, T; Terashima, T; Wang, X; Yamashita, T, 2016) |
| "Metformin is an attractive agent for chemoprevention because it is inexpensive, has a favorable safety profile, and is well tolerated over long time periods." | 1.43 | Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. ( Chung, RT; DePeralta, DK; Fuchs, BC; Ghoshal, S; Lanuti, M; Lauwers, GY; Schmidt, B; Tanabe, KK; Wei, L, 2016) |
| "Patients with nonalcoholic steatohepatitis (NASH) had similar demographic and anthropometric features, but a higher prevalence of type 2 diabetes (T2D; p = 0." | 1.43 | Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. ( Borroni, V; Bugianesi, E; Craxi, A; Dongiovanni, P; Fargion, S; Fracanzani, AL; Pelusi, S; Petta, S; Rosso, C; Valenti, L, 2016) |
| "Metformin-treated CCl4-cirrhotic rats had lower PP and hepatic vascular resistance than vehicle-treated rats, without significant changes in MAP or PBF." | 1.42 | Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. ( Bosch, J; Erice, E; García-Calderó, H; García-Pagán, JC; Gracia-Sancho, J; Lafoz, E; Sarin, SK; Tripathi, DM, 2015) |
| "A total of 302/479 (63%) NAFLD patients (mean age: 47 ± 13 year) were included with a follow-up period of 12." | 1.39 | NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. ( Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S, 2013) |
| "Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes." | 1.38 | Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (6.49) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (7.79) | 29.6817 |
| 2010's | 38 (49.35) | 24.3611 |
| 2020's | 28 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhamid, AM | 1 |
| Youssef, ME | 1 |
| Abd El-Fattah, EE | 1 |
| Gobba, NA | 1 |
| Gaafar, AGA | 1 |
| Girgis, S | 1 |
| Shata, A | 1 |
| Hafez, AM | 1 |
| El-Ahwany, E | 1 |
| Amin, NA | 1 |
| Shahien, MA | 1 |
| Abd-Eldayem, MA | 1 |
| Abou-Elrous, M | 1 |
| Saber, S | 1 |
| Lavynenko, O | 1 |
| Abdul-Ghani, M | 1 |
| Alatrach, M | 1 |
| Puckett, C | 1 |
| Adams, J | 1 |
| Abdelgani, S | 1 |
| Alkhouri, N | 1 |
| Triplitt, C | 1 |
| Clarke, GD | 1 |
| Vasquez, JA | 1 |
| Li, J | 8 |
| Cersosimo, E | 1 |
| Gastaldelli, A | 1 |
| DeFronzo, RA | 1 |
| Hydes, TJ | 1 |
| Cuthbertson, DJ | 1 |
| Graef, S | 1 |
| Berhane, S | 1 |
| Teng, M | 1 |
| Skowronska, A | 1 |
| Singh, P | 1 |
| Dhanaraj, S | 1 |
| Tahrani, A | 1 |
| Johnson, PJ | 1 |
| Omar, ZMM | 1 |
| Ahmed, AA | 1 |
| El-Bakry, MH | 1 |
| Ahmed, MA | 1 |
| Hasan, A | 1 |
| Tapper, EB | 1 |
| Zhao, Z | 2 |
| Mazumder, N | 1 |
| Parikh, ND | 1 |
| Su, Y | 2 |
| Lu, S | 1 |
| Hou, C | 2 |
| Ren, K | 2 |
| Wang, M | 2 |
| Liu, X | 5 |
| Zhao, S | 3 |
| Zhou, ST | 1 |
| Cui, W | 1 |
| Kong, L | 1 |
| Yang, X | 3 |
| Tsai, PC | 1 |
| Kuo, HT | 1 |
| Hung, CH | 1 |
| Tseng, KC | 1 |
| Lai, HC | 1 |
| Peng, CY | 1 |
| Wang, JH | 1 |
| Chen, JJ | 1 |
| Lee, PL | 1 |
| Chien, RN | 1 |
| Yang, CC | 1 |
| Lo, GH | 1 |
| Kao, JH | 1 |
| Liu, CJ | 1 |
| Liu, CH | 1 |
| Yan, SL | 1 |
| Bair, MJ | 1 |
| Lin, CY | 1 |
| Su, WW | 1 |
| Chu, CH | 2 |
| Chen, CJ | 1 |
| Tung, SY | 1 |
| Tai, CM | 1 |
| Lin, CW | 1 |
| Lo, CC | 1 |
| Cheng, PN | 1 |
| Chiu, YC | 1 |
| Wang, CC | 1 |
| Cheng, JS | 1 |
| Tsai, WL | 1 |
| Lin, HC | 1 |
| Huang, YH | 2 |
| Yeh, ML | 1 |
| Huang, CF | 1 |
| Hsieh, MH | 1 |
| Huang, JF | 1 |
| Dai, CY | 1 |
| Chung, WL | 1 |
| Chen, CY | 1 |
| Yu, ML | 1 |
| Zhang, W | 1 |
| Lv, Y | 1 |
| Huo, F | 1 |
| Zhang, Y | 5 |
| Yin, C | 1 |
| Zhang, A | 2 |
| Qian, F | 1 |
| Li, Y | 6 |
| Li, B | 3 |
| Yang, F | 1 |
| Hu, C | 1 |
| Sun, W | 1 |
| Huang, Y | 2 |
| Zhou, D | 1 |
| Yang, T | 3 |
| Guan, Q | 1 |
| Shi, JS | 1 |
| Xu, ZH | 1 |
| Geng, Y | 1 |
| Alshahrani, MY | 1 |
| Ebrahim, HA | 1 |
| Alqahtani, SM | 1 |
| Bayoumy, NM | 1 |
| Kamar, SS | 2 |
| ShamsEldeen, AM | 1 |
| Haidara, MA | 2 |
| Al-Ani, B | 2 |
| Albawardi, A | 1 |
| Stevens, LJ | 1 |
| Dubbeld, J | 1 |
| Doppenberg, JB | 1 |
| van Hoek, B | 1 |
| Menke, AL | 1 |
| Donkers, JM | 1 |
| Alsharaa, A | 1 |
| de Vries, A | 1 |
| Vaes, WHJ | 1 |
| Knibbe, CAJ | 1 |
| van de Steeg, E | 1 |
| Alwayn, IPJ | 1 |
| Shelley, K | 1 |
| Articolo, A | 1 |
| Luthra, R | 1 |
| Charlton, M | 1 |
| Ratziu, V | 1 |
| Pais, R | 1 |
| Huo, RR | 1 |
| Liang, JR | 1 |
| He, FY | 1 |
| Xu, BR | 1 |
| Ma, L | 1 |
| Yuan, WP | 1 |
| Dogru, T | 1 |
| Kırık, A | 1 |
| Sonmez, A | 1 |
| Vilar-Gomez, E | 4 |
| Chalasani, N | 5 |
| Calzadilla-Bertot, L | 1 |
| Wong, VW | 1 |
| Castellanos, M | 1 |
| Aller-de la Fuente, R | 1 |
| Eslam, M | 1 |
| Wong, GL | 1 |
| George, J | 3 |
| Romero-Gomez, M | 2 |
| Adams, LA | 1 |
| Khneizer, G | 1 |
| Rizvi, S | 1 |
| Gawrieh, S | 3 |
| Mahjoubin-Tehran, M | 1 |
| De Vincentis, A | 1 |
| Mikhailidis, DP | 1 |
| Atkin, SL | 1 |
| Mantzoros, CS | 1 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 2 |
| Siddiqui, MT | 1 |
| Amin, H | 1 |
| Garg, R | 1 |
| Chadalavada, P | 1 |
| Al-Yaman, W | 1 |
| Lopez, R | 1 |
| Singh, A | 2 |
| Kaplan, DE | 2 |
| Serper, M | 2 |
| John, BV | 2 |
| Tessiatore, KM | 1 |
| Lerer, R | 1 |
| Mehta, R | 1 |
| Fox, R | 1 |
| Aytaman, A | 1 |
| Baytarian, M | 1 |
| Hunt, K | 1 |
| Albrecht, J | 1 |
| Taddei, TH | 1 |
| Lin, CH | 1 |
| Kohli, R | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 2 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 11 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Chen, Y | 3 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Wang, J | 4 |
| Zhang, E | 1 |
| Zhang, J | 3 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Wang, Y | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 2 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Ren, Y | 1 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 2 |
| Wang, W | 1 |
| Wang, S | 2 |
| Hou, J | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 1 |
| Zhu, J | 2 |
| Zhang, L | 3 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Wang, X | 6 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 1 |
| Zhang, M | 4 |
| Zhang, H | 1 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 2 |
| Liu, Y | 4 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 5 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 2 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 2 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 2 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 2 |
| He, Z | 1 |
| Chen, B | 1 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 2 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 2 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Lee, HW | 1 |
| Lee, JS | 1 |
| Kim, BK | 1 |
| Park, JY | 1 |
| Kim, DY | 1 |
| Ahn, SH | 1 |
| Kim, SU | 1 |
| Rittig, N | 2 |
| Aagaard, NK | 2 |
| Villadsen, GE | 2 |
| Sandahl, TD | 2 |
| Jessen, N | 2 |
| Grønbaek, H | 2 |
| Yen, FS | 1 |
| Hou, MC | 1 |
| Hwu, CM | 1 |
| Lo, YR | 1 |
| Shin, SJ | 1 |
| Hsu, CC | 1 |
| Saffo, S | 1 |
| Mahmud, N | 1 |
| Ross, JS | 1 |
| Taddei, T | 1 |
| Harlow, KE | 1 |
| Pike, F | 1 |
| Yates, KP | 1 |
| Wilson, LA | 1 |
| Cummings, OW | 2 |
| Rosenberg, WM | 1 |
| Molleston, JP | 1 |
| Fan, K | 1 |
| Lin, L | 1 |
| Ge, P | 1 |
| Dai, J | 1 |
| Hu, K | 1 |
| Ko, MT | 1 |
| Huang, HC | 1 |
| Lee, WS | 1 |
| Chuang, CL | 1 |
| Hsin, IF | 1 |
| Hsu, SJ | 1 |
| Lee, FY | 1 |
| Lee, SD | 1 |
| Liu, CW | 1 |
| Yang, YY | 1 |
| Nguyen, G | 1 |
| Park, SY | 2 |
| Le, CT | 1 |
| Park, WS | 1 |
| Choi, DH | 1 |
| Cho, EH | 1 |
| Caussy, C | 1 |
| Hsu, C | 1 |
| Lo, MT | 1 |
| Liu, A | 1 |
| Bettencourt, R | 1 |
| Ajmera, VH | 1 |
| Bassirian, S | 1 |
| Hooker, J | 1 |
| Sy, E | 1 |
| Richards, L | 1 |
| Schork, N | 1 |
| Schnabl, B | 1 |
| Brenner, DA | 1 |
| Sirlin, CB | 1 |
| Chen, CH | 1 |
| Loomba, R | 2 |
| Dong, G | 1 |
| Lin, X | 1 |
| Gao, D | 1 |
| Ren, Z | 1 |
| Chen, R | 1 |
| Al-Hashem, F | 1 |
| Al-Humayed, S | 1 |
| Amin, SN | 1 |
| Mansy, SS | 1 |
| Hassan, S | 1 |
| Abdel-Salam, LO | 1 |
| Ellatif, MA | 1 |
| Alfaifi, M | 1 |
| Handzlik, G | 1 |
| Holecki, M | 1 |
| Kozaczka, J | 1 |
| Kukla, M | 1 |
| Wyskida, K | 1 |
| Kędzierski, L | 1 |
| Pawlicki, K | 1 |
| Duława, J | 1 |
| Jiao, Y | 1 |
| Xing, Y | 1 |
| Gao, P | 1 |
| Das, BK | 1 |
| Choukimath, SM | 1 |
| Gadad, PC | 1 |
| Vuppalanchi, R | 2 |
| Desai, AP | 1 |
| Ghabril, M | 1 |
| Saxena, R | 1 |
| Ianiro, G | 1 |
| Ponziani, FR | 1 |
| Gasbarrini, A | 1 |
| Cammarota, G | 1 |
| Treeprasertsuk, S | 1 |
| Björnsson, E | 1 |
| Enders, F | 1 |
| Suwanwalaikorn, S | 1 |
| Lindor, KD | 1 |
| Harris, K | 1 |
| Smith, L | 1 |
| Harmsen, WS | 1 |
| Mettler, TA | 1 |
| Kim, WR | 1 |
| Roberts, RO | 1 |
| Therneau, TM | 1 |
| Roberts, LR | 1 |
| Chaiteerakij, R | 1 |
| Pariente, A | 1 |
| Katsura, A | 1 |
| Morishita, A | 1 |
| Iwama, H | 1 |
| Tani, J | 1 |
| Sakamoto, T | 1 |
| Tatsuta, M | 1 |
| Toyota, Y | 1 |
| Fujita, K | 1 |
| Kato, K | 2 |
| Maeda, E | 1 |
| Nomura, T | 1 |
| Miyoshi, H | 1 |
| Yoneyama, H | 1 |
| Himoto, T | 1 |
| Fujiwara, S | 1 |
| Kobara, H | 1 |
| Mori, H | 1 |
| Niki, T | 1 |
| Ono, M | 1 |
| Hirashima, M | 1 |
| Masaki, T | 1 |
| Jung, GS | 1 |
| Jeon, JH | 1 |
| Choi, YK | 1 |
| Jang, SY | 1 |
| Kim, MK | 1 |
| Shin, EC | 1 |
| Jeong, WI | 1 |
| Lee, IK | 1 |
| Kang, YN | 1 |
| Park, KG | 1 |
| Tripathi, DM | 1 |
| Erice, E | 1 |
| Lafoz, E | 1 |
| García-Calderó, H | 1 |
| Sarin, SK | 1 |
| Bosch, J | 1 |
| Gracia-Sancho, J | 1 |
| García-Pagán, JC | 1 |
| Traussnigg, S | 1 |
| Kienbacher, C | 1 |
| Halilbasic, E | 1 |
| Rechling, C | 1 |
| Kazemi-Shirazi, L | 1 |
| Hofer, H | 1 |
| Munda, P | 1 |
| Trauner, M | 1 |
| Honda, M | 1 |
| Shirasaki, T | 1 |
| Terashima, T | 1 |
| Kawaguchi, K | 1 |
| Nakamura, M | 1 |
| Oishi, N | 1 |
| Shimakami, T | 1 |
| Okada, H | 1 |
| Arai, K | 1 |
| Yamashita, T | 2 |
| Sakai, Y | 1 |
| Mizukoshi, E | 1 |
| Kaneko, S | 2 |
| DePeralta, DK | 1 |
| Ghoshal, S | 1 |
| Schmidt, B | 1 |
| Lauwers, GY | 1 |
| Lanuti, M | 1 |
| Chung, RT | 1 |
| Tanabe, KK | 1 |
| Fuchs, BC | 1 |
| Elkrief, L | 1 |
| Rautou, PE | 1 |
| Sarin, S | 1 |
| Valla, D | 1 |
| Paradis, V | 1 |
| Moreau, R | 1 |
| Doyle, MA | 1 |
| Singer, J | 1 |
| Lee, T | 1 |
| Muir, M | 1 |
| Cooper, C | 1 |
| Shen, C | 1 |
| Peng, C | 1 |
| Shen, B | 1 |
| Zhu, Z | 1 |
| Xu, N | 1 |
| Li, T | 1 |
| Xie, J | 1 |
| Pelusi, S | 1 |
| Petta, S | 1 |
| Rosso, C | 1 |
| Borroni, V | 1 |
| Fracanzani, AL | 1 |
| Dongiovanni, P | 1 |
| Craxi, A | 1 |
| Bugianesi, E | 2 |
| Fargion, S | 1 |
| Valenti, L | 1 |
| Kasmari, AJ | 1 |
| Welch, A | 1 |
| Liu, G | 1 |
| Leslie, D | 1 |
| McGarrity, T | 1 |
| Riley, T | 1 |
| Raszeja-Wyszomirska, J | 1 |
| Lawniczak, M | 1 |
| Marlicz, W | 1 |
| Miezyńska-Kurtycz, J | 1 |
| Milkiewicz, P | 1 |
| González Jiménez, E | 1 |
| Schmidt Río-Valle, J | 1 |
| Álvarez Ferre, J | 1 |
| Nkontchou, G | 1 |
| Cosson, E | 1 |
| Aout, M | 1 |
| Mahmoudi, A | 1 |
| Bourcier, V | 1 |
| Charif, I | 1 |
| Ganne-Carrie, N | 1 |
| Grando-Lemaire, V | 1 |
| Vicaut, E | 1 |
| Trinchet, JC | 1 |
| Beaugrand, M | 1 |
| Popov, VB | 1 |
| Lim, JK | 1 |
| Kita, Y | 1 |
| Takamura, T | 1 |
| Misu, H | 1 |
| Ota, T | 1 |
| Kurita, S | 1 |
| Takeshita, Y | 1 |
| Uno, M | 1 |
| Matsuzawa-Nagata, N | 1 |
| Ando, H | 1 |
| Fujimura, A | 1 |
| Hayashi, K | 1 |
| Kimura, T | 1 |
| Ni, Y | 1 |
| Otoda, T | 1 |
| Miyamoto, K | 1 |
| Zen, Y | 1 |
| Nakanuma, Y | 1 |
| Ampuero, J | 1 |
| Ranchal, I | 1 |
| Nuñez, D | 1 |
| Díaz-Herrero, Mdel M | 1 |
| Maraver, M | 1 |
| del Campo, JA | 1 |
| Camacho, I | 1 |
| Figueruela, B | 1 |
| Bautista, JD | 1 |
| Gentilcore, E | 1 |
| Manini, R | 1 |
| Natale, S | 1 |
| Vanni, E | 1 |
| Villanova, N | 1 |
| David, E | 1 |
| Rizzetto, M | 1 |
| Marchesini, G | 1 |
| Kluwe, J | 1 |
| Lohse, AW | 1 |
| Kadayifci, A | 1 |
| Merriman, RB | 1 |
| Hoteit, MA | 1 |
| Anania, FA | 1 |
| Selvini, A | 1 |
| Brugi, A | 1 |
| Emanueli, A | 1 |
| Streda, M | 2 |
| Gormsen, J | 2 |
| Laursen, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT04182321] | 60 participants (Actual) | Interventional | 2020-03-13 | Completed | |||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| Improving Treatment and Liver Fibrosis Outcomes With Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients With Insulin Resistance.[NCT02306070] | Phase 2 | 0 participants (Actual) | Interventional | 2016-01-31 | Withdrawn (stopped due to insufficient funding) | ||
| Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| PRIMARY PREVENTION OF HEPATOCELLULAR CARCINOMA BY METFORMIN IN PATIENTS WITH VIRAL C CIRRHOSIS : PROSPECTIVE MULTICENTER STUDY, RANDOMIZED CONTROL TRIAL. Ancillary Study of the ANRS CO12 CirVir Cohort[NCT02319200] | Phase 3 | 11 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Decision of investigator) | ||
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial[NCT00655018] | Phase 2/Phase 3 | 90 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for metformin and Liver Cirrhosis
| Article | Year |
|---|---|
Research progress of metformin in the treatment of liver fibrosis.
Topics: Fibrosis; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Metformin | 2023 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Di | 2021 |
Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
Topics: Adolescent; Alanine Transaminase; Antioxidants; Bariatric Surgery; Child; Child, Preschool; Cysteami | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis.
Topics: Alcoholism; Diabetes Complications; Diabetes Mellitus; Glucose; Hepacivirus; Hepatitis B; Hepatitis | 2019 |
Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Hepatitis C, Chronic; Humans; Hypoglycemic Age | 2013 |
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Topics: Anticholesteremic Agents; Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Disease Progre | 2015 |
Diabetes mellitus in patients with cirrhosis: clinical implications and management.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Hypoglycemic Agents; I | 2016 |
[Non-alcoholic fatty liver disease--new view].
Topics: Biopsy; Causality; Comorbidity; Disease Progression; Fatty Liver; Humans; Hyperglycemia; Insulin Res | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
[Fatty liver and its clinical management in obese adolescents].
Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibros | 2011 |
[Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis].
Topics: Diet Therapy; Exercise Therapy; Fatty Liver; Fatty Liver, Alcoholic; Humans; Liver Cirrhosis; Liver | 2005 |
Treatment of fibrosis in nonalcoholic fatty liver disease.
Topics: Adiponectin; Adipose Tissue; Animals; Antioxidants; Cytokines; Fatty Liver; Humans; Hypoglycemic Age | 2007 |
Glucose tolerance tests in the clinical picture of chronic liver diseases.
Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight | 1975 |
6 trials available for metformin and Liver Cirrhosis
58 other studies available for metformin and Liver Cirrhosis
| Article | Year |
|---|---|
Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride.
Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Carbon Tetrachloride | 2021 |
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty | 2022 |
The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival.
Topics: Carcinoma, Hepatocellular; Child; Diabetes Mellitus, Type 2; Glucose; Humans; Incidence; Liver Cirrh | 2022 |
Metformin versus silymarin as hepatoprotective agents in mice fibrotic model caused by carbon tetrachloride.
Topics: Animals; Antioxidants; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Liver; Liver Ci | 2022 |
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Huma | 2022 |
Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin.
Topics: Animals; Apoptosis; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Metformin; Mice; Mitochondria; N | 2022 |
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2022 |
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Mellitus; Hepatitis C, C | 2023 |
Viscosity-sensitive NIR probe for
Topics: Fluorescent Dyes; Humans; Liver Cirrhosis; Metformin; Viscosity | 2022 |
Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis.
Topics: Adenosine Triphosphate; DNA, Mitochondrial; Electron Transport; Energy Metabolism; Hepatic Stellate | 2023 |
Metformin alleviates liver fibrosis in mice by enriching Lactobacillus sp. MF-1 in the gut microbiota.
Topics: Animals; Gastrointestinal Microbiome; Lactobacillus; Lipopolysaccharides; Liver Cirrhosis; Metformin | 2023 |
Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension.
Topics: AMP-Activated Protein Kinases; Animals; Down-Regulation; Dyslipidemias; Fibrosis; Hypertension; Infl | 2023 |
Novel Explanted Human Liver Model to Assess Hepatic Extraction, Biliary Excretion and Transporter Function.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Digoxin; Drug Interactions; Furosemide; Hep | 2023 |
Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Topics: Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA R | 2023 |
Editorial: it is not a wide-open field for incretins - collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis.
Topics: Diabetes Mellitus; Humans; Incretins; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease | 2019 |
Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Ne | 2019 |
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin; N | 2019 |
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin; N | 2019 |
Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin | 2019 |
Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Liver Neoplasms; Metf | 2021 |
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease | 2021 |
Medications in type-2 diabetics and their association with liver fibrosis.
Topics: Biopsy; Diabetes Mellitus, Type 2; Female; Humans; Liver; Liver Cirrhosis; Male; Metformin; Middle A | 2020 |
Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Liver Neoplasms; Metf | 2021 |
Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Liver Cirrhosis; Male; Metformin; Middle Aged | 2021 |
Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Cirrhosis; Metformin; Proportional Haz | 2022 |
Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.
Topics: Ascites; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Huma | 2021 |
Editorial: metformin for portal hypertension-old dog, new tricks? Authors' reply.
Topics: Humans; Hypertension, Portal; Liver Cirrhosis; Metformin | 2021 |
Metformin mitigates carbon tetrachloride-induced TGF-β1/Smad3 signaling and liver fibrosis in mice.
Topics: Actins; Animals; Antioxidants; Carbon Tetrachloride; Collagen Type I; Heme Oxygenase-1; Hepatic Stel | 2017 |
Metformin reduces intrahepatic fibrosis and intrapulmonary shunts in biliary cirrhotic rats.
Topics: AMP-Activated Protein Kinases; Animals; Cyclooxygenase 1; Hepatopulmonary Syndrome; Liver Cirrhosis; | 2017 |
Dual organ beneficial effects of metformin in cirrhotic rats with hepatopulmonary syndrome.
Topics: Animals; Hepatopulmonary Syndrome; Liver Cirrhosis; Metformin; Rats | 2017 |
Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
Topics: Animals; Cell Line; Dose-Response Relationship, Drug; Down-Regulation; Hepatic Stellate Cells; Human | 2018 |
Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Gastrointestinal Microbiome; Humans; Liver Cirrhosis; | 2018 |
Treatment-damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fibrosis; Growth Dif | 2018 |
Metformin inhibits mTOR-HIF-1α axis and profibrogenic and inflammatory biomarkers in thioacetamide-induced hepatic tissue alterations.
Topics: Animals; Biomarkers; Chronic Disease; Hepatocytes; Hypoxia-Inducible Factor 1, alpha Subunit; Inflam | 2019 |
Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Carcinoma, Hepatocellular; Diabetes Mellitus, Experimen | 2019 |
Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Liver | 2019 |
Letter: improvement of clinical outcomes by metformin in metabolic liver disease-a microbiota-dependent mechanism?
Topics: Diabetes Mellitus; Fibrosis; Humans; Liver; Liver Cirrhosis; Metformin; Microbiota; Non-alcoholic Fa | 2019 |
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Cause of Death; Chi-Square Distribution; Decision Support Te | 2013 |
Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.
Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Liver Cirrhosi | 2014 |
Rationale for conducting a randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: pleiotropic effects hypothesis.
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Metformin | 2014 |
[Do not stop metformin when the patient is cirrhotic].
Topics: Cause of Death; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Cirrhosis; Metformin; | 2014 |
MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Choline Deficiency; Cluster Analysis; Diet; Disease Models, Animal; Gene Expression; Gene E | 2015 |
Small heterodimer partner attenuates profibrogenic features of hepatitis C virus-infected cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Cell Line, Tumor; Gluconeogenesis; Hepaci | 2015 |
Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
Topics: Animals; Blood Pressure; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Metformin; Portal Vein; | 2015 |
Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Hepatitis B Core | 2016 |
Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.
Topics: Animals; Biopsy, Needle; Blotting, Western; Carcinoma, Hepatocellular; Cell Transformation, Neoplast | 2016 |
Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line | 2016 |
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2016 |
Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
Topics: Adult; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Hepatitis C; Human | 2017 |
Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hepatitis C, | 2011 |
Impact of insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis.
Topics: Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Metformin | 2011 |
Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis.
Topics: Animals; Cluster Analysis; Disease Models, Animal; Fatty Liver; Gene Expression Profiling; Gene Expr | 2012 |
Metformin inhibits glutaminase activity and protects against hepatic encephalopathy.
Topics: Age Factors; Ammonia; Diabetes Complications; Enzyme Inhibitors; Female; Glutaminase; Hepatic Enceph | 2012 |
Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2006 |
[On the use of ER 102 in the treatment of diabetes mellitus].
Topics: Adolescent; Adult; Aged; Diabetes Mellitus; Female; Humans; Insulin; Liver Cirrhosis; Male; Metformi | 1967 |
Fibrinolytic activity and haemagglutination inhibition immunoassays.
Topics: Adult; Aged; Biguanides; Clofibrate; Coronary Disease; Ethylestrenol; Female; Fibrin; Fibrinogen; Fi | 1970 |
Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticholesteremic Agents; Arteriosclerosis; Arthritis, Rheu | 1969 |
[Effect of the peroral antidiabetic "Glucophage" on the glucose tolerance test in liver cirrhosis].
Topics: Glucose Tolerance Test; Humans; Injections, Intravenous; Liver Cirrhosis; Metformin; Methods | 1969 |